The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evolving treatment recommendations in myelofibrosis
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses recent updates to the NCCN Guidelines for myelofibrosis and the challenges of translating an evolving treatment landscape into practical recommendations. He highlights the importance of keeping the guidelines nimble as new therapies and combination approaches emerge, while noting recent updates incorporating new approvals in MPNs. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
